Drug Study
Drug Study
Drug Study
De la Rosa
BSN III
Drug Study
Brand Name &
Generic Name
Norvasc
(amlodipine
besylate)
Indication
Mechanism of Action
Dosage
Adverse Reaction
Nursing Consideration
1st-line
treatment
of
HTN
&
myocardial
ischemia.
Reduce the risk
of
coronary
revascularizatio
n & the need for
hospitalization
due to angina in
patients
w/
CHD; reduce the
risk of fatal
CHD, nonfatal
MI & to reduce
the
risk
of
stroke.
HTN,
chronic
stable
angina Initial dose:
5 mg once daily &
may be increased to
a max of 10
mg.Patients
w/
CAD Recommende
d dosage range: 510
mg
once
daily. Ped patients
6-17 yr Initial dose:
2.5-5 mg once
daily. Dose should
not exceed 5 mg
daily.
Flushing, fatigue,
edema, dizziness,
headache,
abdominal pain,
nausea,
palpitations
&
somnolence.
Assessment
History: Allergy to amlodipine, impaired hepatic or
renal function, sick sinus syndrome, heart block,
lactation, CHF
Physical: Skin lesions, color, edema; P, BP, baseline
ECG,
peripheral
perfusion,
auscultation;
R,
adventitious sounds; liver evaluation, GI normal
output; liver and renal function tests, urinalysis
Interventions
WARNING: Monitor patient carefully (BP, cardiac
rhythm, and output) while adjusting drug to therapeutic
dose; use special caution if patient has CHF.
Monitor BP very carefully if patient is also on nitrates.
Monitor cardiac rhythm regularly during stabilization
of dosage and periodically during long-term therapy.
Administer drug without regard to meals.
Teaching points
Take with meals if upset stomach occurs.
You may experience these side effects: Nausea,
vomiting (eat frequent small meals); headache (adjust
lighting, noise, and temperature; medication may be
ordered).
Report irregular heartbeat, shortness of breath, swelling
of
the
hands
or
feet,
pronounced
dizziness, constipation.
Indication
Telmistran
(Micardis)
Treatment of
essential HTN.
Prevention of CV
morbidity &
mortality in
patients 55 yr at
high risk of CV
disease.
Mechanism of Action
Dosage
Adverse Reaction
Nursing Consideration